Major U.S. equities indexes were little changed Monday morning, ahead of retail sector earnings reports and comments from Federal Reserve Chair Jerome Powell due later in the week.

Expanded approval of Wegovy was based on results from the Phase III ESSENCE trial (NCT04822181), which demonstrated ...

People who are prescribed Ozempic to treat type 2 diabetes, but whose insurance does not cover it, or who don’t have ...

Stocks hovered near record highs Monday as investors awaited Fed Chair Jerome Powell’s speech and key earnings from Walmart, Target and Home Depot.

Dow Jones Top Company Headlines at 11 AM ET: Air Canada Halts Guidance as Flight Attendant Strike Continues | Soho ... Air Canada withdrew its financial targets for the year as a strike by flight ...

CNBC's Angelica Peebles joins 'Squawk on the Street' to discuss the latest news on Novo Nordisk, what new FDA approval on its ...

Patients who are prescribed Wegovy or Ozempic can now use GoodRx to access the medications at just $499 a month if they skip ...

Shares of Novo Nordisk ( NVO 4.81%), the Danish pharmaceuticals company famed for Ozempic and Wegovy weight loss drugs, ...

U.S. stock futures edged lower Monday, while Treasuries gained, as traders focused on progress toward a potential peace deal for Ukraine and awaited signals from the Federal Reserve on interest rates.

Novo Nordisk stock gains as FDA expands Wegovy use, while Ozempic price cut aims to boost access and defend market share.

With a new endorsement from the FDA, Novo Nordisk’s Wegovy has picked up its third indication and become the second drug ...

Pharmaceutical powerhouse Novo Nordisk (NYSE:NVO) is charging 3.1% higher to trade at $54.10, after its weight-loss drug ...